


PHARMACEUTICAL 2021



ORAMED PHARMACEUTICALS INC. Rank 137 of 409





PHARMACEUTICAL 2021

ORAMED PHARMACEUTICALS INC. Rank 137 of 409



The relative strengths and weaknesses of ORAMED PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ORAMED PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 99% points. The greatest weakness of ORAMED PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is -37%, being 317% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	40,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,536
Liabilities, Non-Current	7,218
Other Assets	4,023
Other Compr. Net Income	0
Other Expenses	444
Other Liabilities	0
Other Net Income	0
Property and Equipment	99
Research and Development	10,235
Revenues	3,400
Selling, General and Administrative Expense	4,232

Output Variable	Value in 1000 USD
Assets	44,633
Liabilities	11,754
Expenses	14,911
Stockholders Equity	32,879
Net Income	-11,511
Comprehensive Net Income	-11,511
Economic Capital Ratio	-37%